U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
Go back to U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 36.28 +0.23 (0.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.05 | 52 Week High | $71.49 | |||
| Open | $35.13 | 52 Week Low | $33.50 | |||
| Day High | $36.68 | P/E | N/A | |||
| Day Low | $35.09 | EPS | $-1.18 | |||
| Volume | 778,073 | |||||
